525 related articles for article (PubMed ID: 23444256)
1. Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis.
Plosker GL
Drugs; 2013 Mar; 73(3):279-91. PubMed ID: 23444256
[TBL] [Abstract][Full Text] [Related]
2. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals.
Okwundu CI; Uthman OA; Okoromah CA
Cochrane Database Syst Rev; 2012 Jul; (7):CD007189. PubMed ID: 22786505
[TBL] [Abstract][Full Text] [Related]
3. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Thigpen MC; Kebaabetswe PM; Paxton LA; Smith DK; Rose CE; Segolodi TM; Henderson FL; Pathak SR; Soud FA; Chillag KL; Mutanhaurwa R; Chirwa LI; Kasonde M; Abebe D; Buliva E; Gvetadze RJ; Johnson S; Sukalac T; Thomas VT; Hart C; Johnson JA; Malotte CK; Hendrix CW; Brooks JT;
N Engl J Med; 2012 Aug; 367(5):423-34. PubMed ID: 22784038
[TBL] [Abstract][Full Text] [Related]
4. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial.
Mugo NR; Hong T; Celum C; Donnell D; Bukusi EA; John-Stewart G; Wangisi J; Were E; Heffron R; Matthews LT; Morrison S; Ngure K; Baeten JM;
JAMA; 2014 Jul 23-30; 312(4):362-71. PubMed ID: 25038355
[TBL] [Abstract][Full Text] [Related]
5. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.
Baeten JM; Donnell D; Mugo NR; Ndase P; Thomas KK; Campbell JD; Wangisi J; Tappero JW; Bukusi EA; Cohen CR; Katabira E; Ronald A; Tumwesigye E; Were E; Fife KH; Kiarie J; Farquhar C; John-Stewart G; Kidoguchi L; Coombs RW; Hendrix C; Marzinke MA; Frenkel L; Haberer JE; Bangsberg D; Celum C;
Lancet Infect Dis; 2014 Nov; 14(11):1055-1064. PubMed ID: 25300863
[TBL] [Abstract][Full Text] [Related]
6. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten JM; Donnell D; Ndase P; Mugo NR; Campbell JD; Wangisi J; Tappero JW; Bukusi EA; Cohen CR; Katabira E; Ronald A; Tumwesigye E; Were E; Fife KH; Kiarie J; Farquhar C; John-Stewart G; Kakia A; Odoyo J; Mucunguzi A; Nakku-Joloba E; Twesigye R; Ngure K; Apaka C; Tamooh H; Gabona F; Mujugira A; Panteleeff D; Thomas KK; Kidoguchi L; Krows M; Revall J; Morrison S; Haugen H; Emmanuel-Ogier M; Ondrejcek L; Coombs RW; Frenkel L; Hendrix C; Bumpus NN; Bangsberg D; Haberer JE; Stevens WS; Lingappa JR; Celum C;
N Engl J Med; 2012 Aug; 367(5):399-410. PubMed ID: 22784037
[TBL] [Abstract][Full Text] [Related]
7. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
Cohen C; Elion R; Ruane P; Shamblaw D; DeJesus E; Rashbaum B; Chuck SL; Yale K; Liu HC; Warren DR; Ramanathan S; Kearney BP
AIDS; 2011 Mar; 25(6):F7-12. PubMed ID: 21412057
[TBL] [Abstract][Full Text] [Related]
8. Preexposure prophylaxis for HIV infection among African women.
Van Damme L; Corneli A; Ahmed K; Agot K; Lombaard J; Kapiga S; Malahleha M; Owino F; Manongi R; Onyango J; Temu L; Monedi MC; Mak'Oketch P; Makanda M; Reblin I; Makatu SE; Saylor L; Kiernan H; Kirkendale S; Wong C; Grant R; Kashuba A; Nanda K; Mandala J; Fransen K; Deese J; Crucitti T; Mastro TD; Taylor D;
N Engl J Med; 2012 Aug; 367(5):411-22. PubMed ID: 22784040
[TBL] [Abstract][Full Text] [Related]
9. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
Celum C; Morrow RA; Donnell D; Hong T; Hendrix CW; Thomas KK; Fife KH; Nakku-Joloba E; Mujugira A; Baeten JM;
Ann Intern Med; 2014 Jul; 161(1):11-9. PubMed ID: 24979446
[TBL] [Abstract][Full Text] [Related]
10. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
Mugwanya KK; Wyatt C; Celum C; Donnell D; Mugo NR; Tappero J; Kiarie J; Ronald A; Baeten JM;
JAMA Intern Med; 2015 Feb; 175(2):246-54. PubMed ID: 25531343
[TBL] [Abstract][Full Text] [Related]
11. Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence.
Celum C; Baeten JM
Curr Opin Infect Dis; 2012 Feb; 25(1):51-7. PubMed ID: 22156901
[TBL] [Abstract][Full Text] [Related]
12. Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial.
Mandala J; Nanda K; Wang M; De Baetselier I; Deese J; Lombaard J; Owino F; Malahleha M; Manongi R; Taylor D; Van Damme L
BMC Pharmacol Toxicol; 2014 Dec; 15():77. PubMed ID: 25539648
[TBL] [Abstract][Full Text] [Related]
13. Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis.
Solomon MM; Lama JR; Glidden DV; Mulligan K; McMahan V; Liu AY; Guanira JV; Veloso VG; Mayer KH; Chariyalertsak S; Schechter M; Bekker LG; Kallás EG; Burns DN; Grant RM;
AIDS; 2014 Mar; 28(6):851-9. PubMed ID: 24499951
[TBL] [Abstract][Full Text] [Related]
14. Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventions.
Donnell D; Hughes JP; Wang L; Chen YQ; Fleming TR
J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2(0 2):S130-4. PubMed ID: 23764624
[TBL] [Abstract][Full Text] [Related]
15. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission.
Patterson KB; Prince HA; Kraft E; Jenkins AJ; Shaheen NJ; Rooney JF; Cohen MS; Kashuba AD
Sci Transl Med; 2011 Dec; 3(112):112re4. PubMed ID: 22158861
[TBL] [Abstract][Full Text] [Related]
16. No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis.
Marcus JL; Glidden DV; Mayer KH; Liu AY; Buchbinder SP; Amico KR; McMahan V; Kallas EG; Montoya-Herrera O; Pilotto J; Grant RM
PLoS One; 2013; 8(12):e81997. PubMed ID: 24367497
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Ogbuagu O; Ruane PJ; Podzamczer D; Salazar LC; Henry K; Asmuth DM; Wohl D; Gilson R; Shao Y; Ebrahimi R; Cox S; Kintu A; Carter C; Das M; Baeten JM; Brainard DM; Whitlock G; Brunetta JM; Kronborg G; Spinner CD;
Lancet HIV; 2021 Jul; 8(7):e397-e407. PubMed ID: 34197772
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results.
Rockstroh JK; DeJesus E; Henry K; Molina JM; Gathe J; Ramanathan S; Wei X; Plummer A; Abram M; Cheng AK; Fordyce MW; Szwarcberg J;
J Acquir Immune Defic Syndr; 2013 Apr; 62(5):483-6. PubMed ID: 23337366
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial.
Liegler T; Abdel-Mohsen M; Bentley LG; Atchison R; Schmidt T; Javier J; Mehrotra M; Eden C; Glidden DV; McMahan V; Anderson PL; Li P; Wong JK; Buchbinder S; Guanira JV; Grant RM;
J Infect Dis; 2014 Oct; 210(8):1217-27. PubMed ID: 24740633
[TBL] [Abstract][Full Text] [Related]
20. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
Dejesus E; Young B; Morales-Ramirez JO; Sloan L; Ward DJ; Flaherty JF; Ebrahimi R; Maa JF; Reilly K; Ecker J; McColl D; Seekins D; Farajallah A;
J Acquir Immune Defic Syndr; 2009 Jun; 51(2):163-74. PubMed ID: 19357529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
